guest ::
| Home > Publications database > Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case report. > print |
| Home > Publications database > Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case report. > print |
| 001 | 285101 | ||
| 005 | 20240229155101.0 | ||
| 024 | 7 | _ | |a 10.1111/bcp.15924 |2 doi |
| 024 | 7 | _ | |a pmid:37815301 |2 pmid |
| 024 | 7 | _ | |a 0306-5251 |2 ISSN |
| 024 | 7 | _ | |a 1365-2125 |2 ISSN |
| 024 | 7 | _ | |a altmetric:155352621 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-02225 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Longuespée, Rémi |0 P:(DE-He78)69f4086396e9a4830b9bdb751b68f2a6 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case report. |
| 260 | _ | _ | |a Oxford |c 2024 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1703857087_1122 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Case report / 2024 Jan;90(1):344-349 / #EA:B350# |
| 520 | _ | _ | |a Short bowel syndrome (SBS) following extensive intestinal resection is often characterized by impaired absorption of orally administered drugs, including tyrosine kinase inhibitors (TKI). We report the case of a patient with EGFR-mutated non-small cell lung carcinoma treated with 80 mg/day of the TKI osimertinib who achieved partial response of the tumour, but was subsequently subjected to a double-barrelled jejunostomy due to ileus. Due to the development of SBS after the bypass surgery, plasma concentrations of osimertinib were monitored using mass spectrometry. The therapeutic drug monitoring confirmed a malabsorption of osimertinib in the patient (108 ng/mL, which is below the 5th percentile of the expected plasma concentration) and was useful to guide adjustments of TKI dosing in order to achieve adequate blood levels (161 ng/mL after increase of the dose to 120 mg/day) in order to maintain tumour control. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a LC-MS/MS |2 Other |
| 650 | _ | 7 | |a MALDI-MS/MS |2 Other |
| 650 | _ | 7 | |a non-small cell lung cancer |2 Other |
| 650 | _ | 7 | |a osimertinib |2 Other |
| 650 | _ | 7 | |a short bowel syndrome |2 Other |
| 650 | _ | 7 | |a therapeutic drug monitoring |2 Other |
| 700 | 1 | _ | |a Kunz, Julia |b 1 |
| 700 | 1 | _ | |a Fresnais, Margaux |b 2 |
| 700 | 1 | _ | |a Foerster, Kathrin I |b 3 |
| 700 | 1 | _ | |a Burhenne, Jürgen |b 4 |
| 700 | 1 | _ | |a Thomas, Michael |b 5 |
| 700 | 1 | _ | |a Kazdal, Daniel |b 6 |
| 700 | 1 | _ | |a Stenzinger, Albrecht |b 7 |
| 700 | 1 | _ | |a Christopoulos, Petros |b 8 |
| 700 | 1 | _ | |a Haefeli, Walter E |0 0000-0003-0672-6876 |b 9 |
| 773 | _ | _ | |a 10.1111/bcp.15924 |g p. bcp.15924 |0 PERI:(DE-600)1498142-7 |n 1 |p 344-349 |t British journal of clinical pharmacology |v 90 |y 2024 |x 0306-5251 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:285101 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)69f4086396e9a4830b9bdb751b68f2a6 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BRIT J CLIN PHARMACO : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-He78)B350-20160331 |k B350 |l Metabolischer Crosstalk bei Krebserkrankungen |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)B350-20160331 |k B350 |l Metabolischer Crosstalk bei Krebserkrankungen |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B350-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|